Jazz Pharmaceuticals (JAZZ)
(Delayed Data from NSDQ)
$107.10 USD
-1.80 (-1.65%)
Updated Apr 17, 2024 04:00 PM ET
After-Market: $107.18 +0.08 (0.07%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth F Momentum B VGM
Price, Consensus and EPS Surprise
JAZZ 107.10 -1.80(-1.65%)
Will JAZZ be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for JAZZ based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for JAZZ
Alkermes' (ALKS) ALKS 2680 Betters Wakefulness in Phase Ib Study
Pharma Stock Roundup: AZN Voydeya Gets FDA Nod, MRK KRAS Inhibitor Enters Phase III
JAZZ: What are Zacks experts saying now?
Zacks Private Portfolio Services
Merck (MRK) Begins Phase III NSCLC Study on KRAS Candidate
Axsome (AXSM) Begins Solriamfetol Binge Eating Phase III Study
Why Is Jazz (JAZZ) Up 1.3% Since Last Earnings Report?
Other News for JAZZ
Jazz Pharmaceuticals to Report 2024 First Quarter Financial Results on May 1, 2024
Eli Lilly obesity therapy succeeds in late-stage trials for sleep disorder
Jazz Pharmaceuticals: Targeting The Low-Hanging Fruit In Oncology Might Pay Off
Breaking Down Jazz Pharmaceuticals: 15 Analysts Share Their Views
Jazz Pharmaceuticals to Showcase Expansive Neuroscience Portfolio at American Academy of Neurology Annual Meeting